The US Food and Drug Administration (FDA) has approved a groundbreaking oral medication, designed to prevent motion-induced vomiting, marking the first new treatment for motion sickness in over 40 years. The drug, known as Nereus and developed by Vanda Pharmaceuticals, introduces a novel approach to addressing this common ailment that affects up to 30% of adults.
Tradipitant, the active ingredient in Nereus, is classified as a neurokinin-1 (NK-1) receptor antagonist. This innovative therapy offers a significant advancement in motion sickness management, as traditional treatments, primarily antihistamines, have long been associated with limited effectiveness and undesirable side effects, including drowsiness.
According to Mihael Polymeropoulos, CEO of Vanda Pharmaceuticals, “For the first time in over 40 years, patients have access to a novel therapy grounded in modern neuropharmacology, offering effective prevention without the limitations of existing options.” This statement highlights the importance of Nereus in improving the quality of life for those prone to motion sickness.
Nereus works by inhibiting the NK-1 receptor located in the brainstem, which plays a critical role in the vomiting reflex triggered by the neurotransmitter substance P. By blocking this receptor, the drug effectively reduces the likelihood of vomiting due to motion.
Clinical Trials and Future Applications
The FDA’s decision was based on findings from three clinical trials, including two Phase III real-world studies that evaluated the drug’s effectiveness in participants traveling on boats. The results demonstrated a significant reduction in vomiting incidents for those taking Nereus compared to a placebo.
While concerns about the long-term safety of Tradipitant were raised, Vanda and the FDA reached an agreement that motion sickness is typically an acute condition. As such, the medication is not intended for prolonged use.
The approval of Nereus is a pivotal moment for individuals suffering from motion sickness, providing a new option for relief. Expected to be available in pharmacies within months, the drug may also undergo further studies to explore its potential in treating other conditions, such as gastroparesis and nausea associated with weight-loss medications.
The trial results were published in the journal Frontiers in Neurology, underscoring the scientific foundation of this new therapy. As Nereus prepares to enter the market, it represents hope for millions seeking effective solutions to a condition that has long been underserved.
